Kicking off #ESMO26 with the best colleagues and friends at the INMC meeting. Excellent leadership by @Liz_htx03. Such exciting times - we’ve defined that neoadjuvant is superior to adjuvant IO. Where do we go next? Identifying risk thresholds for <pCR, biomarkers, new combos, etc.
798 浏览 · 17 赞 · 5 转发 · 1 回复
Impact of BRAF V600K mutation in patients with resectable stage III melanoma: A subgroup analysis of the NADINA trial
https://esmocongress.esmo.org- Ed Williams@EdWilli63968626
@DrBetofMDPhD @Liz_htx03 Some one better send the news to Merck/Moderna!!!! Some how I think they believe in new personal vaccine that they have some data on that might force a comparison going forward of these two schools of thought!!! I do like neo-adjuvant NADINA model and having melanoma present!
来源：Allison Betof, MD, PhD, FASCO · x.com